Can the agreement be e-signed?

Yes. Electronic signatures are valid under the ESIGN Act (15 U.S.C. §7001) and UETA in most states; ensure intent, consent, attribution, and record retention to satisfy legal tests.

Do I need a BAA for PHI?

Yes. When a vendor or CRO will create, receive, maintain, or transmit protected health information, include a Business Associate Agreement to meet HIPAA requirements (45 CFR §164.502).

Is notarization required?

Not typically required for clinical trial agreements, but some institutions or state rules may ask for notarization; check state notary and institutional policies before execution.

How long must records be kept?

Retain study agreements through the active term plus at least 3 years; HIPAA requires six years for health records (45 CFR §164.530(j)); IRS or sponsor rules may extend retention.

Who may sign on behalf of an organization?

An authorized signatory with corporate authority should sign; ensure corporate resolution or delegated authority documentation supports the signer to avoid enforceability challenges.

How do I amend the agreement?

Use a written amendment signed by all parties that references the original agreement; record effective date and retain both amendment and original as part of the study file.

Electronic Signature
Templates
Healthcare
Healthcare Clinical Trial Agreement

Healthcare Clinical Trial Agreement

This template is fully customizable. Edit the text, fill out the fields, and send it for signature. Give it a try!

Healthcare Clinical Trial Agreement

Parties and Effective Date

Sponsor Name Sponsor Address Institution / Clinical Site Name Site Address

This Clinical Trial Agreement (the Agreement) is entered into by Sponsor: and Institution: and is effective as of (Effective Date).

Protocol and Study Details

Protocol Title Protocol Number

Investigational Product / Device: . Study Phase: . Expected Enrollment: .

Study Start Date Study End Date (anticipated)

Scope of Work

Description of Site Responsibilities Principal Investigator Investigator Contact Information

Regulatory Compliance and Ethics

The parties shall conduct the Study in accordance with the approved protocol, applicable laws and regulations, Good Clinical Practice (GCP), and the determinations of the overseeing Institutional Review Board or Independent Ethics Committee (IRB/IEC). The Institution shall obtain and maintain written informed consent from each subject prior to any study-specific procedure.

IRB/IEC Approval Date Informed Consent Responsibility

Investigator will obtain written informed consent in a form approved by the IRB/IEC and shall maintain consent documents in subject files in accordance with applicable law.
Investigator acknowledges obligation to obtain and retain informed consent.

Safety Reporting

Investigator shall promptly report Serious Adverse Events (SAEs) and other safety information as required by the protocol and applicable regulation. Sponsor shall notify Investigator of safety information that may affect the risk/benefit assessment.

Compensation, Budget and Payments

Budget Summary / Total Compensation Payment Schedule and Milestones Billing Contact for Payments

Insurance and Indemnification

Site Insurance Provider Policy Number

Sponsor will indemnify and hold harmless Institution for claims arising from Sponsor's breach of the Agreement or Sponsor-provided product defects, except to the extent caused by Institution's negligence or willful misconduct. Institution will maintain appropriate liability insurance and provide proof upon Sponsor's request.

Confidentiality and Data Handling

Confidential Information Description

All subject-level data supplied to Sponsor shall be de-identified in accordance with applicable law prior to transmission unless otherwise agreed. Ownership of clinical data and case report forms shall be as set forth in this Agreement: Sponsor retains ownership of the study database; Institution retains subject source documents.

Data Transfer / Storage Requirements

Publication and Intellectual Property

Institution may publish aggregated results subject to Sponsor's right to review and propose reasonable redactions to protect confidential information or patentable inventions. Intellectual property arising solely from Sponsor-provided materials belongs to Sponsor; inventions arising solely from Institution's activities belong to Institution; joint inventions will be addressed pursuant to negotiation.

Term, Termination and Remedies

Notices

Sponsor Notices Contact Institution Notices Contact

Representations, Warranties and Certifications

Each party represents that it has the authority to enter into this Agreement and that performance will comply with applicable laws and regulations. Investigator certifies that qualifications and licenses are current and that no conflicts of interest exist that would materially affect performance under this Agreement.

Dispute Resolution and Governing Law

The parties shall attempt in good faith to resolve disputes arising under this Agreement by negotiation. If unresolved, disputes shall be resolved by binding arbitration under the laws mutually agreed by the parties: Governing law: .

Miscellaneous

This Agreement constitutes the entire agreement between the parties with respect to the Study and supersedes prior proposals and agreements. No amendment shall be binding unless in writing and signed by authorized representatives of both parties.

Acknowledgment

By signing below, each party warrants that the individual signing is duly authorized to bind the respective party, and accepts the terms and obligations set forth in this Agreement.

Sponsor (Print Name):

By:

Date:

Institution / PI (Print Name):

By:

Date:

What the Healthcare Clinical Trial Agreement Is and Why It Matters

The Healthcare Clinical Trial Agreement is a contract that documents the legal and operational terms for conducting a clinical study between a sponsor, investigator, research site, and any service providers. It allocates responsibilities for protocol adherence, subject recruitment, data collection, monitoring, safety reporting, budget and payments, intellectual property, publication rights, indemnity, insurance, and termination. The agreement often references protocol appendices, informed consent language, data transfer addenda, and regulatory commitments; in the U.S. parties must also account for ESIGN/UETA e-signature rules and HIPAA protections when PHI is exchanged.

Why a Clear Agreement Reduces Risk and Keeps Trials on Track

A well‑drafted Healthcare Clinical Trial Agreement clarifies financial obligations, safety reporting responsibilities, data ownership, and publication rights; it reduces disputes, supports HIPAA and FDA compliance, and documents operational controls needed for audits and sponsor oversight.

Who Typically Completes and Relies on This Agreement

Clinical trial stakeholders who draft, review, or depend on the agreement include sponsors, investigational sites, institutional review boards (IRBs), and contract research organizations (CROs).

Study sponsors and funders: manage budget, oversight, and regulatory reporting obligations for the trial.
Investigators and site staff: accept site responsibilities for recruitment, consent, recordkeeping, and subject safety.
CROs, labs, and vendors: deliver contracted services, manage data, and maintain quality control and monitoring.

Clear assignment of duties among these stakeholders helps ensure regulatory filings, invoicing, and safety reporting proceed without administrative delays.

Key Signatory Roles and What They Do

Sponsor Representative

The sponsor signatory negotiates budget and indemnity terms, approves study milestones, and coordinates with legal and finance teams to ensure funding and reporting commitments are met across the sponsor organization.

Principal Investigator

The PI signs for the site to confirm staffing, informed consent compliance, subject safety oversight, and accurate completion of case report forms; the PI coordinates local regulatory submissions and site-level obligations.

Essential Security and Compliance Elements to Include

PHI Handling: Specify permitted uses and disclosures

Business Associate: Include BAA when a vendor accesses PHI

Encryption: Require TLS 1.2/1.3 in transit, AES-256 at rest

Access Controls: Role-based access and least privilege

Audit Trail: Maintain tamper-evident logs and timestamps

21 CFR Controls: Address Part 11 requirements for regulated records

Primary Legal and Operational Risks to Watch For

Breach Liability: Civil damages and reputational harm

Regulatory Fines: HIPAA or FDA enforcement penalties

Enrollment Delays: Missed milestones, lost funding

Data Integrity: Noncompliant records risk rejection

Publication Disputes: Authorship conflicts and injunction risk

Indemnity Gaps: Uncapped liability exposures

Common Preparation Mistakes to Avoid

Failing to attach the final protocol and budget schedule causes ambiguity about deliverables and payment triggers, creating billing disputes and audit findings.
Omitting a BAA or HIPAA-specific data handling terms when PHI is exchanged can lead to regulatory noncompliance and civil penalties under 45 CFR §164.530(j).
Using vague IP or publication language without defining data ownership or embargo periods often results in protracted negotiations or litigation.
Not specifying the governing law or forum for disputes increases uncertainty and can complicate cross‑state enforcement of contractual rights.

Step-by-Step: Completing a Healthcare Clinical Trial Agreement

Follow these practical steps to prepare, negotiate, and execute a Clinical Trial Agreement with clear responsibilities and compliant data controls.

01

Assemble documents: Gather protocol, budget, consent template, and vendor SOWs
02

Identify parties: List legal entity names, PI, and authorized signers
03

Negotiate terms: Resolve indemnity, IP, payment, and termination clauses
04

Execute and store: Obtain signatures and retain an audit trail copy

Where to File, Send, or Submit Copies of the Agreement

After execution, route the final agreement and its exhibits to the primary stakeholders and compliance systems for retention and audit readiness.

Sponsor Records: Central archive and clinical operations repository
Site File: Retain original in site regulatory binder
IRB: Submit final agreement or site addenda as required
Regulatory Authority: Provide on inspection or per request

Key Clauses to Include in a Professional Agreement

A comprehensive Healthcare Clinical Trial Agreement addresses operational, financial, legal, and privacy concerns in sufficient detail to support regulatory compliance and governance.

Scope of Work

Define study activities, enrollment targets, and deliverables precisely, including protocol number, study population, and any site-specific deviations to avoid scope disputes.

Payment and Budget

Specify milestone payments, invoicing procedures, allowable costs, travel reimbursement, and remedies for overpayment to prevent audit exceptions and billing conflicts.

Data Ownership

Allocate rights to raw data, datasets, and derived analyses, and define permitted secondary uses and journal publication procedures to protect sponsors and investigators.

Safety Reporting

Clarify timelines and responsible parties for notifying sponsors, IRBs, and regulators of adverse events and SUSARs to meet FDA expectations and protect subjects.

Confidentiality

Include defined confidential information, permitted disclosures, duration of obligations, and carve-outs for regulatory submissions and required reporting.

Termination and Liability

Set termination triggers, wind‑down conduct, insurance requirements, and indemnity allocations to limit exposure and enable orderly study closure.

Real-World Examples and How Agreements Were Used

Practical examples show how organizations use Clinical Trial Agreements to resolve operational and compliance needs during study setup and execution.

Fertility Centers Example

A clinical network standardized agreement language to centralize HIPAA safeguards and signature workflows across sites

The team used e-signatures and BAAs
Standardization reduced contract turnaround and improved audit readiness while keeping patient privacy protections consistent.

Large Sponsor Case

An enterprise sponsor implemented uniform indemnity and publication clauses across multiple countries

They required centralized signatory approval
Consistent clauses minimized renegotiation and supported regulatory filings in multiple jurisdictions with a single set of core terms.

How to Configure an Online Completion Workflow

Set up an electronic workflow that places fields, applies conditional logic, and captures secure signer authentication for auditability.

Field	Configuration
Signature Authentication	Email link, SMS code, or stronger KBA as required
Conditional Fields	Show budget or HIPAA clauses based on party selection
Bulk Send	Use for multiple site addenda or identical attachments
Retention Settings	Enable immutable audit trail and exportable certificate

Digital Signing and eSubmission Considerations

Choose a signing platform that supports audit trails, HIPAA/BAA arrangements, and integrations with document repositories.

Integrations: Salesforce, NetSuite, Google Workspace supported
File formats: PDF, DOCX, and native templates accepted
Authentication: SMS, email, or advanced KBA options

eSignature Vendor Pricing and Feature Snapshot for Clinical Trial Agreements

Compare common vendor price points and feature availability when choosing a platform to execute Healthcare Clinical Trial Agreements and associated BAAs.

	signNow	DocuSign	Adobe Sign	PandaDoc	HelloSign
Starting Price	$8/user/mo	$15/user/mo	$14/user/mo	$19/user/mo	$15/user/mo
Free Trial	7-day free trial	Varies	Varies	Varies	Varies
Bulk Send	Yes	Yes	Yes	Yes	No
Audit Trail	Yes	Yes	Yes	Yes	Yes
HIPAA Compliant	Yes	Yes	Yes	No	No

Frequently Asked Questions About Healthcare Clinical Trial Agreements

Answers to common questions on e-signing, HIPAA, notarization, retention, and amendments for Clinical Trial Agreements.

Need help? Contact support

Can the agreement be e-signed?
Yes. Electronic signatures are valid under the ESIGN Act (15 U.S.C. §7001) and UETA in most states; ensure intent, consent, attribution, and record retention to satisfy legal tests.
Do I need a BAA for PHI?
Yes. When a vendor or CRO will create, receive, maintain, or transmit protected health information, include a Business Associate Agreement to meet HIPAA requirements (45 CFR §164.502).
Is notarization required?
Not typically required for clinical trial agreements, but some institutions or state rules may ask for notarization; check state notary and institutional policies before execution.
How long must records be kept?
Retain study agreements through the active term plus at least 3 years; HIPAA requires six years for health records (45 CFR §164.530(j)); IRS or sponsor rules may extend retention.
Who may sign on behalf of an organization?
An authorized signatory with corporate authority should sign; ensure corporate resolution or delegated authority documentation supports the signer to avoid enforceability challenges.
How do I amend the agreement?
Use a written amendment signed by all parties that references the original agreement; record effective date and retain both amendment and original as part of the study file.

be ready to get more

Join over 28 million airSlate SignNow users

Sign Now